Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT04120623
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT04120623
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04120623. Randomized; single masking; primary purpose treatment. Start 2019-10-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dapagliflozin 10 MG
- Intervention (Drug)
- Insulin Aspart
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
Record details
- Record id
cardio:ct-nct04120623- Content hash
09bf8424bed6252d0f76fd54222fa6a162f3f2c9849821d43fbda18a0c188a56